China-based Miaoshou Doctor, which provides telehealth services and operates an online pharmaceuticals marketplace, raises ~$84M Series D
China Money Network :
Context & Ripple Effects
Miaoshou Doctor's ~$84M Series D lands mid-2020, when capital is flooding into Chinese digital health across every layer of the stack: Yaoshibang's earlier ~$65.7M Series C established online pharmacy as a fundable category, DXY followed later the same year with a $500M raise for its doctor-and-consumer portal, and MediTrust Health's $308M Series C in 2021 showed payment-and-pharmacy platforms commanding the largest checks.
What distinguishes Miaoshou Doctor is the pairing: telehealth consultation plus an online pharmaceuticals marketplace in one company, rather than a single-service play. That combination sits at the intersection of the two categories investors have been funding separately since 2018.
First-order effects
- The round gives Miaoshou Doctor the capital to scale both sides of its model — telehealth consultations that generate prescriptions and a marketplace that fulfills them — directly against online pharmacy incumbents like Yaoshibang.
Second-order effects
- Rival digital health platforms face pressure to close the same loop: DXY's doctor-facing portal and MediTrust's payment-plus-pharmacy stack each cover part of the journey, and a funded competitor owning consultation-through-delivery forces them to add the missing pieces.
Third-order effects
- If the funding pattern holds, Chinese digital health consolidates around integrated platforms that bundle consultation, prescription, payment, and drug delivery, squeezing standalone single-service apps — the structure Yaoshibang pioneered and the mega-rounds to DXY and MediTrust have been capitalizing.
The trend: Chinese digital health is consolidating from single-service apps into full-stack telehealth-plus-pharmacy platforms, with round sizes climbing from tens of millions to hundreds of millions.